MX2022000373A - Combinacion de ibuprofeno y tramadol para aliviar el dolor. - Google Patents

Combinacion de ibuprofeno y tramadol para aliviar el dolor.

Info

Publication number
MX2022000373A
MX2022000373A MX2022000373A MX2022000373A MX2022000373A MX 2022000373 A MX2022000373 A MX 2022000373A MX 2022000373 A MX2022000373 A MX 2022000373A MX 2022000373 A MX2022000373 A MX 2022000373A MX 2022000373 A MX2022000373 A MX 2022000373A
Authority
MX
Mexico
Prior art keywords
tramadol
combination
ibuprofen
pain
relieving pain
Prior art date
Application number
MX2022000373A
Other languages
English (en)
Inventor
Calvo Antonia Gómez
Menéndez Nuria Sanz
De La Torre Marta Vicario
Alonso Fernando García
Pérez Antonio Portolés
Serna Luis Narciso Santé
Butrón María Del Rosario Salas
Castrillón Emilio Vargas
Pérez Carlos Calandria
Córdoba Raquel Horcajada
Ruiz Ángel José Muñoz
García Jose Angel Sánchez
Gonzalez Ester Duart
Original Assignee
Farmalider Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmalider Sa filed Critical Farmalider Sa
Publication of MX2022000373A publication Critical patent/MX2022000373A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a la combinación de ibuprofeno en forma de una sal farmacéuticamente aceptable, y tramadol, o una sal farmacéuticamente aceptable del mismo, para su uso en el tratamiento del dolor en seres humanos, en la que la dosificación de ibuprofeno en la combinación está comprendida entre 350 mg y 450 mg y la dosificación de tramadol está comprendida entre 35 mg y 40 mg, expresada como peso equivalente de clorhidrato de tramadol. La combinación es adecuada para el tratamiento del dolor de moderado a severo, de origen crónico o agudo, y es particularmente efectiva para aquellos pacientes que padecen dolor más intenso. También se refiere a una composición farmacéutica que comprende dicha combinación de dosis fija de ibuprofeno y tramadol.
MX2022000373A 2019-07-09 2020-07-08 Combinacion de ibuprofeno y tramadol para aliviar el dolor. MX2022000373A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382583 2019-07-09
PCT/EP2020/069306 WO2021005129A1 (en) 2019-07-09 2020-07-08 Combination of ibuprofen and tramadol for relieving pain

Publications (1)

Publication Number Publication Date
MX2022000373A true MX2022000373A (es) 2022-02-10

Family

ID=67480112

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000373A MX2022000373A (es) 2019-07-09 2020-07-08 Combinacion de ibuprofeno y tramadol para aliviar el dolor.

Country Status (20)

Country Link
US (1) US20220249414A1 (es)
EP (1) EP3996699B1 (es)
JP (1) JP2022540854A (es)
CN (1) CN114080221B (es)
AU (1) AU2020309160A1 (es)
BR (1) BR112022000242A2 (es)
CA (1) CA3145632C (es)
DK (1) DK3996699T3 (es)
ES (1) ES2952013T3 (es)
FI (1) FI3996699T3 (es)
HR (1) HRP20230677T1 (es)
HU (1) HUE062529T2 (es)
MA (1) MA56341B1 (es)
MD (1) MD3996699T2 (es)
MX (1) MX2022000373A (es)
PL (1) PL3996699T3 (es)
PT (1) PT3996699T (es)
RS (1) RS64500B1 (es)
SI (1) SI3996699T1 (es)
WO (1) WO2021005129A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB971700A (en) 1961-02-02 1964-09-30 Boots Pure Drug Co Ltd Anti-Inflammatory Agents
US3652589A (en) 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
GB1497044A (en) 1974-03-07 1978-01-05 Prodotti Antibiotici Spa Salts of phenyl-alkanoic acids
US5516803A (en) * 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
AU661723B2 (en) * 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
EP2149546A1 (en) * 2008-07-31 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. Salts of tramadol and ibuprofen and their crystal form in the treatment of pain
ES2356762B1 (es) * 2009-09-04 2011-11-24 Farmalider S.A. Composicion farmaceutica de ibuprofeno, tramadol y un aminoacido basico, procedimiento para su preparacion y utilizacion de la misma.
ES2423866B1 (es) 2012-02-22 2014-06-10 Farmalider, S.A. Composición farmaceútica de ibuprofeno y tramadol para inyección
ES2540151B1 (es) * 2013-10-11 2016-02-29 Farmalider S.A. Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico

Also Published As

Publication number Publication date
EP3996699B1 (en) 2023-06-28
DK3996699T3 (da) 2023-07-24
ES2952013T3 (es) 2023-10-26
HRP20230677T1 (hr) 2023-10-13
SI3996699T1 (sl) 2023-10-30
CN114080221B (zh) 2023-12-05
US20220249414A1 (en) 2022-08-11
JP2022540854A (ja) 2022-09-20
PT3996699T (pt) 2023-07-27
CA3145632C (en) 2024-03-12
CN114080221A (zh) 2022-02-22
RS64500B1 (sr) 2023-09-29
EP3996699A1 (en) 2022-05-18
WO2021005129A1 (en) 2021-01-14
HUE062529T2 (hu) 2023-11-28
MA56341B1 (fr) 2023-07-31
PL3996699T3 (pl) 2023-10-30
AU2020309160A1 (en) 2022-02-17
CA3145632A1 (en) 2021-01-14
FI3996699T3 (fi) 2023-08-01
MD3996699T2 (ro) 2023-11-30
BR112022000242A2 (pt) 2022-05-31

Similar Documents

Publication Publication Date Title
MX2019012884A (es) Terapia de combinacion.
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
CA2632207C (en) Use of calcitonin for the treatment of ra
MX2021009199A (es) Conjugado de farmaco de dos ligandos y uso del mismo.
NZ605469A (en) Nalbuphine-based formulations and uses thereof
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
MX2007010886A (es) Metodos y formulaciones de acarbosa para tratar constipacion cronica.
JP2004537500A5 (es)
JP2016505050A5 (es)
WO2022026622A3 (en) Treatment of viral diseases
MX2022000373A (es) Combinacion de ibuprofeno y tramadol para aliviar el dolor.
RU2010154623A (ru) Производные 1-аминоалкилциклогексана для лечения расстройств сна
HRP20211661T1 (hr) Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti
MX2018000963A (es) Composicion farmaceutica sinergica del enantiomero activo s-ketorolaco trometamina y clorhidrato de tramadol.
HRP20230693T1 (hr) Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti
ZA202200331B (en) Naltrexone formulation
WO2020013776A3 (en) Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation
MX2021003030A (es) Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion.
CA2469702A1 (en) Darifenacin for use in the treatment of urgency induced by overactive bladder
MX2022000426A (es) Telmisartan para el tratamiento de la hipertension en perros.